News

In a study recently published in the JAMA Network, researchers sought to investigate the use of patient-facing digital health technologies for opioid use disorder (OUD) by organizations in the United States with ACO contracts. The search began as it was unclear whether these technologies serve as substitute or complements to traditional SUD treatment resources in health care organizations.

Emissions from healthcare facilities contribute to climate change, and climate change, in turn, is presenting new challenges for healthcare.

Bryant Hoyal, VP of Client Services, Strategic Accounts at Relatient suggests filling appointment schedules with patients based on their specific needs through best practices is an efficient way to drive revenue, as well as balance workflows for staff. Outside of scheduling tools, Hoyal stressed the importance of being a data-driven organization to understand and control the workflow of your practice.

Approvals this week include Opill, the first nonprescription oral contraceptive, the use of Veklury for COVID-19 in patients with severe renal impairment, and the earlier use of Leqvio for in heart disease. In addition, Takeda pulled its application for a dengue vaccine.

This week, the FDA granted full approval to the Alzheimer’s drug Leqembi, set an action for review of zolbetuximab to treat gastric cancers and rejected Amneal’s new drug application (NDA) Parkinson’s disease treatment.

In this population-based cohort study, researchers compared the risks of incident cardiovascular, neurological, and mental health conditions and rheumatoid arthritis in a year following COVID hospitalization to three different groups: pre-pandemic hospitalization for influenza, pre-pandemic hospitalization for sepsis and hospitalization for sepsis post-pandemic.

Approvals this week include: a $2.9 million gene therapy for hemophilia A; a pediatric growth hormone; the first cell therapy for type 1 diabetes; a new alopecia drug; a therapy for generalized myasthenia gravis; and full approval for Blincyto in B-cell ALL. The agency also rejected a higher dose of Eylea and set an action for hemophilia B gene therapy.